Raymond James Financial Inc. Invests $2.43 Million in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Raymond James Financial Inc. acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 84,883 shares of the specialty pharmaceutical company's stock, valued at approximately $2,432,000. Raymond James Financial Inc. owned about 0.26% of Collegium Pharmaceutical at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in COLL. Nisa Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after purchasing an additional 316 shares during the period. TD Private Client Wealth LLC raised its stake in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock worth $66,000 after buying an additional 483 shares during the period. Caprock Group LLC boosted its holdings in Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company's stock worth $249,000 after acquiring an additional 543 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Collegium Pharmaceutical by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock valued at $196,000 after acquiring an additional 642 shares during the period. Finally, Sanctuary Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 5.3% during the fourth quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company's stock valued at $542,000 after acquiring an additional 952 shares in the last quarter.

Remove Ads

Collegium Pharmaceutical Stock Up 2.1 %

Shares of COLL stock traded up $0.61 on Wednesday, hitting $30.00. The stock had a trading volume of 216,377 shares, compared to its average volume of 437,710. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The stock has a market cap of $944.58 million, a price-to-earnings ratio of 12.93 and a beta of 0.99. The business has a 50 day moving average of $30.16 and a 200 day moving average of $32.28. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analysts Set New Price Targets

COLL has been the topic of a number of recent research reports. Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a report on Tuesday, February 4th. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price on the stock in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.60.

Insiders Place Their Bets

In related news, CFO Colleen Tupper sold 10,445 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares in the company, valued at approximately $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,193 shares of company stock valued at $3,243,594. Insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.